Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.

about

Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.

Item

http://www.wikidata.org/entity/Q41828518

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Somatostatin receptor subtypes ...... esistant) prostatic carcinoma.

@en

type

Item

label

Somatostatin receptor subtypes ...... esistant) prostatic carcinoma.

@en

prefLabel

Somatostatin receptor subtypes ...... esistant) prostatic carcinoma.

@en

P1476

Somatostatin receptor subtypes ...... esistant) prostatic carcinoma.

@en

P2093

Aldo V Bono

http://www.w3.org/2001/XMLSchema#string

Antonio Lopez-Beltran

http://www.w3.org/2001/XMLSchema#string

Doriana Morichetti

http://www.w3.org/2001/XMLSchema#string

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

Marina Scarpelli

http://www.w3.org/2001/XMLSchema#string

Roberta Mazzucchelli

http://www.w3.org/2001/XMLSchema#string

Ziya Kirkali

http://www.w3.org/2001/XMLSchema#string

P2860

Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study

Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines

Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.

Somatostatin receptors in human prostate and prostate cancer.

Somatostatin receptors and regulation of cell proliferation.

Somatostatin receptors: from basic science to clinical approach--thyroid.

Chemotherapy targeted to cancers through tumoral hormone receptors.

Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.

Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer.

P304

242-247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJA.2010.100

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rodolfo Montironi

P577

2010-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49676866

http://www.w3.org/2001/XMLSchema#string

P698

21151154

http://www.w3.org/2001/XMLSchema#string

P932

3739180

http://www.w3.org/2001/XMLSchema#string